Latest On Minerva Neurosciences, Inc (NERV):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-20 03:00 EST | News | Minerva Neurosciences: Up About 250 Percent Since April With An FDA Catalyst Ahead | N/A |  |
| 2023-05-15 12:54 EST | News | Minerva Neurosciences GAAP EPS of -$1.31 | N/A | |
| 2023-05-15 12:54 EST | News | Minerva Neurosciences, Inc. (NERV) Q1 2023 Earnings Call Transcript | N/A | |
| 2023-05-10 18:38 EST | News | Minerva soars ~10% as schizophrenia drug gets FDA review | N/A | |
| 2023-05-01 12:04 EST | News | Minerva stock rises ~15% as FDA accepts filing for schizophrenia drug | N/A | |
About Minerva Neurosciences, Inc (NERV):
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, a compound in Phase III clinical trial for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated i read more...n 2007 and is headquartered in Waltham, Massachusetts.
General
- Name Minerva Neurosciences, Inc
- Symbol NERV
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 11
- Fiscal Year EndDecember
- IPO Date2014-07-01
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.minervaneurosciences.com
Valuation
- Trailing PE 65.52
- Forward PE 13.72
- Price/Sales (Trailing 12 Mt.) 3.27
- Price/Book (Most Recent Quarter) 2.67
- Enterprise Value Revenue 2.8
- Enterprise Value EBITDA 57
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$0.22
- Next Year EPS Estimate -$0.74
- Next Quarter EPS Estimate $0.45
- Profit Margin 5%
- Operating Margin 4%
- Return on Assets 2%
- Return on Equity 5%
- Revenue 41.18 million
- Earnings Per Share $0.05
- Revenue Per Share $1.01
- Gross Profit 19.14 million
- Quarterly Earnings Growth 0%
Highlights
- Market Capitalization 134.36 million
- EBITDA 1.86 million
- Analyst Target Price $7
- Book Value Per Share $1.23
Share Statistics
- Shares Outstanding 42.72 million
- Shares Float 37.24 million
- % Held by Insiders 362%
- % Held by Institutions 70.19%
- Shares Short 2.45 million
- Shares Short Prior Month 2.15 million
- Short Ratio 4.3
- Short % of Float 8%
- Short % of Shares Outstanding 6%
Technicals
- Beta 1.35
- 52 Week High $15.22
- 52 Week Low $2.24
- 50 Day Moving Average 3.3
- 200 Day Moving Average 3.16
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
Minerva Neurosciences, Inc (NERV) Dividend Calendar:
Minerva Neurosciences, Inc (NERV) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Minerva Neurosciences, Inc (NERV) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Minerva Neurosciences, Inc (NERV) Chart:
Minerva Neurosciences, Inc (NERV) News:
Below you will find a list of latest news for Minerva Neurosciences, Inc (NERV) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Minerva Neurosciences, Inc (NERV) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest NERV Trades:
Minerva Neurosciences, Inc (NERV) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-11-02 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-10-14 | 8-K (Current report) | |
| 2020-10-14 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-14 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-14 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-14 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-14 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-14 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-14 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-11 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-08 | 8-K (Current report) | |
| 2020-08-17 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-17 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-17 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-17 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-17 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-17 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-17 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-17 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-10 | S-8 (Securities to be offered to employees in employee benefit plans) | |
Minerva Neurosciences, Inc (NERV) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Minerva Neurosciences, Inc (NERV). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 362%
Institutional Ownership: 7019%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-09-10 | HEEK G JAN VAN | Director | Buy | 7,000.00 | 2.97 | 20,790.00 | 20,333.00 | |
| 2020-05-26 | Frederick W Ahlholm | SVP, Chief Accounting Officer | Sell | 8,339.00 | 15.00 | 125,085.00 | 6,884.00 | |
| 2019-12-17 | Frederick W Ahlholm | SVP, Chief Accounting Officer | Sell | 1,557.00 | 7.10 | 11,054.70 | 15,223.00 | |
| 2019-12-17 | Geoff Race | EVP, CFO & CBO | Sell | 5,826.00 | 7.10 | 41,364.60 | 205,044.00 | |
| 2019-12-17 | Joseph H. Reilly | SVP & Chief Operating Officer | Sell | 2,724.00 | 7.10 | 19,340.40 | 26,225.00 | |
| 2019-12-17 | Remy Luthringer | CEO | Sell | 2,412.00 | 7.10 | 17,125.20 | 49,040.00 | |
| 2019-12-14 | Frederick W Ahlholm | SVP, Chief Accounting Officer | Buy | 5,000.00 | 16,780.00 | | ||
| 2019-12-14 | Geoff Race | EVP, CFO & CBO | Buy | 12,500.00 | 210,870.00 | | ||
| 2019-12-14 | Joseph H. Reilly | SVP & Chief Operating Officer | Buy | 8,750.00 | 28,949.00 | | ||
| 2019-12-14 | Remy Luthringer | CEO | Buy | 18,750.00 | 51,452.00 | | ||
| 2019-12-12 | Richard E. Russell | President | Sell | 3,113.00 | 7.42 | 23,098.46 | 33,770.00 | |
| 2019-06-27 | WILLIAM F DOYLE | Director | Buy | 3,500.00 | 5.50 | 19,250.00 | 26,111.00 | |
| 2019-06-26 | JERYL L HILLEMAN | Director | Buy | 1,000.00 | 5.25 | 5,250.00 | 1,000.00 | |
| 2019-06-26 | HANS PETER HASLER | Director | Buy | 10,000.00 | 5.60 | 56,000.00 | 10,000.00 | |
| 2019-06-26 | HEEK G JAN VAN | Director | Buy | 10,000.00 | 5.37 | 53,700.00 | 13,333.00 | |
| 2019-06-26 | David Kupfer | Director | Buy | 10,000.00 | 5.55 | 55,500.00 | 219,188.00 | |
| 2019-06-24 | Venture Associates III Ltd Index | 10% Share Holder | Sell | 197,000.00 | 6.01 | 1,184,836.80 | 3,899,189.00 | |
| 2019-06-20 | Venture Associates III Ltd Index | 10% Share Holder | Sell | 33,575.00 | 4.34 | 145,759.15 | 4,096,189.00 | |
| 2019-06-19 | Venture Associates III Ltd Index | 10% Share Holder | Sell | 77,243.00 | 4.44 | 343,152.03 | 4,129,764.00 | |
| 2019-06-18 | Venture Associates III Ltd Index | 10% Share Holder | Sell | 49,675.00 | 4.44 | 220,522.23 | 4,207,007.00 | |